1. Introduction {#sec1}
===============

Urinary tract infections (UTIs) are one of the most common infectious diseases \[[@B1]--[@B3]\]. They may be symptomatic or asymptomatic, and either type of infection can result in serious sequelae if not appropriately treated \[[@B4]\]. Although different causative agents can be responsible for UTIs, bacteria are the major cause being responsible for more than 95% of UTI cases \[[@B5]\]. In this context, *E. coli* is the most prevalent organism and is solely responsible for the majority of these infections. An accurate and prompt diagnosis is important in shortening the disease course and for preventing the ascent of the infection to the upper urinary tract \[[@B6]\]. Treatment of UTI is often started empirically. UTIs are often treated with different broad-spectrum antibiotics when one with a narrow spectrum of activity may be appropriate because of concerns about infection with resistant organisms, and antimicrobial susceptibility testing of the urinary pathogens constitutes the basis for antibiotic therapy. However, in view of the increasing bacterial resistance, regular monitoring of resistance patterns is necessary to improve guidelines for empirical antibiotic therapy \[[@B6]--[@B8]\]. The present study aims at analyzing the infectious epidemiology of UTIs in a general university hospital located in Beirut over a period of ten years. In addition, it examines the susceptibility profiles of *E. coli* between 2000 and 2009.

2. Material and Methods {#sec2}
=======================

2.1. Study Design {#sec2.1}
-----------------

This is a retrospective study conducted at the Microbiology section of the Medical Laboratories of the Saint George Hospital-University Medical Center in Beirut and covering ten years (2000 to 2009). The population included all in- and outpatients with documented UTI. This included 10,013 different Gram-positive and Gram-negative bacteria in addition to *Candida albicans* and *Candida sp.* There were 6,708 (66.99%) samples from female patients and 3,305 (33.01%) from male patients. Adult patients were sampled by clean catch midstream urine, and children aged less than 3 years were sampled using sterile urine bags. Only a single positive culture per patient was included in the analysis within the period of three months.

2.2. Isolation and Identification of Organisms {#sec2.2}
----------------------------------------------

Samples for urine culture were tested within half an hour of sampling. All samples were inoculated on blood agar as well as Mac Conckey agar and incubated at 37°C for 24 hours, and for 48 hours in negative cases. A specimen was considered positive for UTI in the light of the number of yielded colonies (≥10^5^ cfu/mL) and the cytology of the urine through microscopic detection of bacteriuria and PMNs (≥8 leukocytes/mm^3^). However, lower colony counts associated with significant pyuria or low PMN count associated with significant colony counts was considered and analyzed in the light of the clinical picture and the patient\'s immunological status. Bacterial identification was based on standard culture and biochemical characteristics of isolates.

Gram-negative bacteria were identified by standard biochemical tests \[[@B5], [@B6]\]. Gram-positive microorganisms were identified with the corresponding recommended laboratory tests.

2.3. Susceptibility Testing {#sec2.3}
---------------------------

Antimicrobial susceptibility of *E. coli* was tested by the disk diffusion method according to the CLSI recommendations, using the Mueller-Hinton agar \[[@B6]\]. Antimicrobial agents tested were ampicillin, amoxicillin-clavulanic acid, aztreonam, cephalothin, cefoxitin, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, cefipime, piperacillin, piperacillin-tazobactam, imipenem, gentamycin, tobramycin, norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and tetracycline. The CLSI-ESBL phenotypic confirmatory test with ceftazidime, cefotaxime, ceftriaxone, and cefixime was performed for all the isolates by disk diffusion method on the Mueller-Hinton agar plates with and without 10 *μ*g of amoxiclav. Susceptibility test results were interpreted according to the criteria established by the Clinical & Laboratory Standard Institute (CLSI). A minimum of 5 mm increase in the zone of diameter of third-generation cephalosporins, tested in combination with amoxiclav versus its zone when tested alone, was considered indicative of ESBL production. *E. coli*ATCC 25922 was used as ESBL-negative and *K. pneumoniae*700603 was used as ESBL-positive reference strain. Statistical analysis: variables were expressed as percentages.

3. Results {#sec3}
==========

Over a 10-year period, a total of 10,013 positive urine isolates including 6,071 *E. coli* were analyzed.

Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} show the microorganisms most frequently isolated from these positive urine cultures. As expected, *E. coli* was the most frequent isolate throughout the ten years (average of 60.64% of the total isolates). It was followed by *Klebsiella pneumoniae* where rate of isolation ranged between 6.1 and 9.9%. The next most frequently isolated bacteria were *Proteus sp., Pseudomonas aeruginosa, Enterococcus sp.,*and*Streptococcus agalactiae*. *Candida albicans* and *Candida sp.* were commonly isolated; however, their clinical significance was not always evident. If *Candida* and minor bacterial isolates are not included, Gram-negative bacteria accounted for 92% of the UTI, while Gram-positive infections were responsible only for 8%.

Analysis of the results according to patient gender (not shown) indicated that although *E. coli* is the predominant isolated pathogen from both sexes, it occurred more frequently in women (69.8% in women compared to 61.4% in men.) The trend of infectious etiology in the population did not really differ over the 10-year period.

The percentages of susceptibility (and subsequently of nonsusceptibility including both resistant and intermediately resistant strains) of *E. coli* isolates to the panel of antibiotics which are commonly used to treat *Escherichia*infections are shown in [Table 3](#tab3){ref-type="table"}. The lowest percentage of susceptibility was manifested against piperacillin (between 9 and 24%) followed by ampicillin (between 26 and 38%), whereas an absolute susceptibility was observed with imipenem (100%). In general, the urinary isolates showed a slightly better susceptibility profile in comparison to all the hospital isolates of *E. coli*. Over the successive years, the susceptibility to cephalosporins, including generations 3 and 4, tends to decrease; this is coupled by an increase in the production of ESBL as shown in [Table 4](#tab4){ref-type="table"} where ESBL production goes from 2.3% in 2000 to 16.8% in 2009 for the urinary isolates.

[Table 5](#tab5){ref-type="table"} shows the susceptibility profiles of ESBL producing *E. coli* to families of antibiotics other than *beta*-lactams. Tigecycline, amikacin, and piperacillin-tazobactam seem to have the highest antibacterial activity on these organisms.

[Table 6](#tab6){ref-type="table"} shows the percentages of simultaneous resistance in the urinary isolates of *E. coli*to various families of antimicrobial agents.

4. Discussion {#sec4}
=============

This study shows the distribution of microbial species and antibiotic susceptibility patterns of *E. coli* isolated from Lebanese patients with UTIs. Saint George Hospital is a 300-bed hospital located in Beirut; however, it is one of the busiest hospitals in the country and receives patients from different areas of Lebanon. In this retrospective study, no clinical data are provided, and this constitutes by itself a limitation. Subsequently, important information related to symptomatic versus asymptomatic, complicated versus uncomplicated UTI, and health-care-associated versus catheter-related UTIs could not be addressed and discussed. The majority of pathogens were isolated from women (69.8%). It has been extensively reported that adult women have a higher prevalence of UTI than men, principally owing to anatomic and physical factors \[[@B9]\].

Antibiotic resistance is a major clinical problem in treating infections caused by these microorganisms. The resistance to the antimicrobials has increased over the years. Resistance rates vary from country to country \[[@B10]\]. In Lebanon, there is an evidence for increase in ESBL producing Enterobacteriaceae. This was previously reported in our hospital as well as in other institutions in the country \[[@B11]--[@B15]\]

In this study, *E. coli* accounted for approximately 61% of all clinically significant urinary isolates and 76.8% of all Enterobacteriaceae. This is consistent with the findings of previous studies in which *E. coli*was the predominant pathogen isolated from patients with UTIs \[[@B16], [@B17]\]. The rate of isolation of *Klebsiella pneumoniae*might be described as high when compared to other studies \[[@B16], [@B17]\]; however, this can be explained by the fact that our study includes both hospital and acquired UTI.

*E. coli*isolates from urinary infections show a similar pattern of susceptibility to those isolated from all body site infections although with a more enhanced susceptibility percentages. Aminopenicillins do not constitute a therapeutic option in this population; even the combination amoxicillin-clavulanic acid does not seem to offer important alternative for treatment. In view of the increasing ESBL production, all cephalosporins activities are affected and challenged by these inactivating enzymes. Imipenem remains the only antibiotic with 100% of susceptibility.

It is pretty alarming to note that between 7.3 and 13.8% of the urinary isolates of *E. coli*show simultaneous resistance to third-generation cephalosporins, aminoglycosides, and fluoroquinolones. A genetic investigation on these isolates should be performed in order to identify the mechanisms of resistance and discover whether they are correlated to each other or independently occurring.
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###### 

The organisms most commonly isolated from Lebanese patients with UTI between 2000 and 2004 at Saint George Hospital University Medical Center, Beirut.

                                   The microorganisms most commonly isolated from Lebanese patients with UTI between 2000 and 2004                                                        
  -------------------------------- ------------------------------------------------------------------------------------------------- ------ ----- ------ ------ ------ ----- ------ ----- ------
  *Acinetobacter sp.*              3                                                                                                 0.5    4     0.5    2      0.2    0     0.0    14    1.3
  *Candida albicans*               15                                                                                                2.4    12    1.6    23     2.4    26    2.4    31    2.9
  *Candida sp.*                    16                                                                                                2.5    22    2.9    28     2.9    47    4.3    34    3.1
  *Citrobacter sp.*                6                                                                                                 0.9    11    1.5    19     2.0    17    1.5    15    1.4
  *Enterobacter sp.*               4                                                                                                 0.6    12    1.6    14     1.5    6     0.5    16    1.5
  *Enterococcus faecalis*          17                                                                                                2.7    18    2.4    28     2.9    48    4.4    20    1.9
  *Enterococcus faecium*           6                                                                                                 0.9    18    2.4    20     2.1    30    2.7    35    3.2
  *Escherichia coli*               395                                                                                               62.5   440   58.3   575    59.8   637   57.9   661   61.1
  *Klebsiella sp.*                 48                                                                                                7.6    75    9.9    59     6.1    85    7.7    79    7.3
  *Morganella morganii*            5                                                                                                 0.8    4     0.5    11     1.1    14    1.3    14    1.3
  *Proteus sp.*                    45                                                                                                7.1    50    6.6    72     7.5    74    6.7    65    6.0
  *Pseudomonas aeruginosa*         30                                                                                                4.7    38    5.0    45     4.7    35    3.2    51    4.7
  *Pseudomonas sp.*                0                                                                                                 0.0    2     0.3    1      0.1    1     0.1    0     0.0
  *Staphylococcus aureus*          3                                                                                                 0.5    6     0.8    3      0.3    7     0.6    9     0.8
  *Staphylococcus saprophyticus*   6                                                                                                 0.9    7     0.9    5      0.5    2     0.2    3     0.3
  *Streptococcus agalactiae*       20                                                                                                3.2    15    2.0    14     1.5    25    2.3    18    1.7
  *Streptococcus, Group D*         1                                                                                                 0.2    2     0.3    4      0.4    1     0.1    6     0.6
  Other minor organisms            12                                                                                                1.9    19    2.5    38     4.0    45    4.1    10    0.9
                                                                                                                                                                                          
  Total isolates                   632                                                                                               755    961   1100   1081                             

###### 

The organisms most commonly isolated from Lebanese patients with UTI between 2000 and 2004 at Saint George Hospital University Medical Center, Beirut.

                                   The microorganisms most commonly isolated from Lebanese patients with UTI between 2005 and 2009                                                         
  -------------------------------- ------------------------------------------------------------------------------------------------- ------ ------ ------ ------ ------ ----- ------ ----- ------
  *Acinetobacter sp.*              19                                                                                                1.9    14     1.2    18     1.6    16    1.3    5     0.5
  *Candida albicans*               14                                                                                                1.4    37     3.3    27     2.4    29    2.4    25    2.5
  *Candida sp.*                    29                                                                                                2.9    57     5.1    34     3.0    31    2.6    35    3.5
  *Citrobacter sp.*                15                                                                                                1.5    18     1.6    19     1.7    16    1.3    9     0.9
  *Enterobacter sp.*               16                                                                                                1.6    22     2.0    14     1.2    19    1.6    6     0.6
  *Enterococcus faecalis*          14                                                                                                1.4    15     1.3    20     1.8    14    1.2    15    1.5
  *Enterococcus faecium*           32                                                                                                3.2    25     2.2    34     3.0    34    2.8    6     0.6
  *Escherichia coli*               609                                                                                               60.2   711    63.4   688    60.7   727   60.0   628   62.5
  *Klebsiella sp.*                 92                                                                                                9.1    84     7.5    100    8.8    118   9.7    90    9.0
  *Morganella morganii*            13                                                                                                1.3    6      0.5    10     0.9    24    2.0    7     0.7
  *Proteus sp.*                    57                                                                                                5.6    53     4.7    70     6.2    73    6.0    63    6.3
  *Pseudomonas aeruginosa*         39                                                                                                3.9    27     2.4    40     3.5    44    3.6    41    4.1
  *Pseudomonas sp.*                0                                                                                                 0.0    6      0.5    0      0.0    6     0.5    3     0.3
  *Staphylococcus aureus*          7                                                                                                 0.7    4      0.4    6      0.5    4     0.3    10    1.0
  *Staphylococcus saprophyticus*   0                                                                                                 0.0    5      0.4    1      0.1    2     0.2    3     0.3
  *Streptococcus agalactiae*       27                                                                                                2.7    14     1.2    16     1.4    16    1.3    8     0.8
  *Streptococcus, Group D*         1                                                                                                 0.1    1      0.1    1      0.1    0     0.0    1     0.1
  Other minor organisms            28                                                                                                2.8    23     2.0    36     3.2    38    3.1    50    5.0
                                                                                                                                                                                           
  Total isolates                   1012                                                                                              1122   1134   1211   1005                             

###### 

Susceptibility profiles of urinary and nonurinary isolates of *E. coli* collected from Lebanese patients between 2000 and 2009 at Saint George Hospital University Medical Center, Beirut.

                                Percentages of susceptibility of *E. coli* isolated from Lebanese patients                                                                                       
  ------------ --------- ------ ---------------------------------------------------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ----- ----- ----- ---- ---- ---- ----
  2000         General   620    37                                                                           58   95   54   92   89   96   96   95   97   20    93    100   89    88   75   78   51
  Urinary      395       38     59                                                                           98   57   97   95   96   96   97   99   24   94    100   92    89    88   83   54   
  Nonurinary   225       35     56                                                                           91   52   81   82   95   95   94   96   17   93    100   85    88    59   70   52   
  2001         General   697    28                                                                           56   92   49   91   82   93   93   92   95   18    93    100   89    88   75   78   48
  Urinary      440       32     63                                                                           94   51   92   88   96   96   97   97   22   94    100   92    89    88   83   51   
  Nonurinary   257       22     49                                                                           91   47   89   74   91   89   87   92   13   91    100   87    86    61   73   45   
  2002         General   901    30                                                                           62   92   60   96   84   94   94   92   96   12    96    100   83    79   64   76   50
  Urinary      699       34     69                                                                           94   62   97   90   96   97   97   97   16   97    100   86    80    77   81   53   
  Nonurinary   202       26     54                                                                           89   56   93   77   90   91   87   94   7    93    100   81    77    50   73   45   
  2003         General   1221   28                                                                           58   81   54   96   83   83   83   82   83   13    95    100   78    74   60   77   48
  Urinary      637       32     65                                                                           83   56   97   89   89   90   89   90   17   96    100   81    75    73   82   51   
  Nonurinary   516       24     50                                                                           78   51   94   77   76   80   74   77   10   94    100   75    74    48   72   44   
  2004         General   1094   28                                                                           65   52   59   95   77   82   82   82   82   9     99    100   78    81   62   65   64
  Urinary      661       32     72                                                                           54   61   96   83   88   89   89   89   13   100   100   81    82    75   70   67   
  Nonurinary   433       25     59                                                                           50   56   93   71   75   75   75   74   7    97    100   78    79    52   63   60   
  2005         General   998    26                                                                           61   53   49   95   76   80   80   80   81   10    98    100   76    99   58   62   51
  Urinary      609       30     68                                                                           55   51   96   82   86   87   87   88   14   99    100   79    100   71   67   54   
  Nonurinary   389       24     55                                                                           51   48   93   72   75   73   72   74   8    97    100   74    99    51   60   49   
  2006         General   1072   29                                                                           64   79   54   95   80   83   83   83   83   10    99    100   79    99   43   71   49
  Urinary      711       33     71                                                                           81   56   96   86   89   90   90   90   14   100   100   82    100   56   76   52   
  Nonurinary   361       25     60                                                                           79   55   94   75   79   78   78   78   8    99    100   76    99    39   74   48   
  2007         General   1049   29                                                                           65   81   59   95   78   81   81   81   81   10    99    100   80    99   44   48   47
  Urinary      688       34     72                                                                           83   61   96   84   87   88   88   88   14   100   100   83    100   57   53   50   
  Nonurinary   361       23     60                                                                           80   58   93   73   78   77   77   77   7    99    100   78    99    36   45   44   
  2008         General   1098   28                                                                           66   77   55   89   73   78   80   80   80   9     99    100   75    93   42   47   45
  Urinary      727       30     67                                                                           80   55   96   78   82   88   88   89   15   99    100   82    98    62   52   51   
  Nonurinary   371       25     65                                                                           76   54   84   69   75   73   73   73   5    98    100   70    89    39   45   40   
  2009         General   1011   26                                                                           60   79   46   96   76   79   79   79   79   13    98    100   79    99   44   46   47
  Urinary      628       31     69                                                                           81   47   96   84   86   86   87   53   18   99    100   83    99    63   52   51   
  Nonurinary   383       23     53                                                                           79   45   96   69   74   74   75   80   11   99    100   76    99    35   41   44   

###### 

ESBL production in *E. coli* collected from Lebanese patients between 2000 and 2009 at the Saint George Hospital University Medical Center, Beirut. U: urinary isolates, NU: nonurinary isolates.

                       ESBL production in *E. coli* isolated between 2000 and 2009                                                                                               
  -------------------- ------------------------------------------------------------- ------ ------ ------ ------ ------ ------- ------ ------ ------ ------ ------ ------ ------ ------
  Number of isolates   620                                                           395    225    697    440    257    901     699    202    1221   637    584    1094   661    433
  \% of ESBL           2.3                                                           2.1    2.3    4      3.9    4.3    9.8     9.9    9.5    13.6   14.5   12.1   12.9   11.0   14.1
                       2005                                                          2006   2007   2008   2009                                                                   
                                                                                                                                                                                 
  Isolates             All                                                           U      NU     All    U      NU     All     U      NU     All    U      NU     All    U      NU
                                                                                                                                                                                 
  Number of isolates   998                                                           609    389    1072   711    361    1049    688    361    1098   727    371    1011   628    383
  \% of ESBL           20.3                                                          15.7   26.1   17.4   15.6   19.1   19.45   19.2   19.8   19.4   17.1   22.0   18.6   16.8   21.8

###### 

Susceptibility profiles of ESBL producing *E. coli* collected from Lebanese patients between 2005 and 2009 at the Saint George Hospital-University Medical Center, Beirut.

                      Percentages of susceptibility of ESBL producing *E. coli*                                      
  ------------ ------ ----------------------------------------------------------- ------ ------ ------ ------ ------ ------
  2005         All    90.5                                                        85.6   29.8   97.6   39.4   ND     21.1
  Urinary      92.3   87.6                                                        35.2   97.5   41.1   ND     16.4   
  Nonurinary   88.2   83.5                                                        25.1   97.8   37.1   ND     17.9   
  2006         All    97.9                                                        80.7   27.3   93.3   24.1   ND     17.6
  Urinary      95.6   84.4                                                        33.5   94.1   40.8   ND     18.8   
  Nonurinary   98.3   76.9                                                        22.1   93.5   18.9   ND     16.5   
  2007         All    93.6                                                        81.4   30.1   92.2   23.5   89.6   23.1
  Urinary      91.2   87.5                                                        22.4   89.9   36.8   91.2   25.7   
  Nonurinary   90.2   75.6                                                        36.8   95.4   41.3   93.2   19.1   
  2008         All    94.2                                                        80.6   27.8   94.1   25.6   87.4   18.8
  Urinary      89.1   82.4                                                        24.4   87.9   26.6   91.4   21.1   
  Nonurinary   97.3   77.1                                                        32.2   98.8   23.9   82.1   15.5   
  2009         All    93.6                                                        83.4   30.8   94.2   19.5   91.6   19.6
  Urinary      94.6   84.5                                                        36.1   96.6   25.4   94.4   19.5   
  Nonurinary   91.8   82.2                                                        26.3   92.2   10.6   89.9   19.2   

###### 

Multiple resistance of urinary isolates of *E. coli.*

                                                                                      Percentage of resistance profiles                      
  ----------------------------------------------------------------------------------- ----------------------------------- ----- ----- ------ -----
  Resistant to aminoglycosides and fluoroquinolones                                   3.2                                 2.6   3.1   3      3.7
  Resistant to 3rd-Generation cephalosporins and fluoroquinolones                     3.6                                 3     4.9   8.2    9.6
  Resistant to 3rd-Generation cephalosporins and aminoglycosides                      3.9                                 3.4   3.5   2.5    3.1
  Resistant to 3rd-Generation cephalosporins, aminoglycosides, and fluoroquinolones   8.7                                 9     9.8   13.8   7.3
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